Avillion Gets Initial Funding, Helps Pharma Pick Up Pace
By Nuala Moran
Tuesday, January 29, 2013
Pharma's productivity woes have spawned a new UK company, Avillion LLP, which is offering to plug between $50 million and $100 million into the co-development of Phase III assets.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.